The Guardian14 jun 2026Innovatie
Automatisch samengesteld met AI uit de vermelde bronnen
Poolbeg Pharma will start an intermediate clinical trial of its oral drug POLB 001 at six NHS hospitals, enrolling 30 patients receiving J&J’s teclistamab for blood cancer, with trial leadership by the University of Manchester and the Christie NHS Foundation Trust. The compound, acquired from Palau Pharma and originally developed for chronic inflammation, aims to prevent cytokine release syndrome, which currently has no approved preventive therapy and affects about 70% of patients on cancer immunotherapies. Poolbeg expects interim data by the end of summer and estimates a potential global market of $10 bn, based on a $20,000 per-treatment price.